{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:46:41Z","timestamp":1759538801339,"version":"build-2065373602"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011072","name":"the University of North Carolina at Chapel Hill Center for AIDS Research","doi-asserted-by":"publisher","award":["P30AI050410"],"award-info":[{"award-number":["P30AI050410"]}],"id":[{"id":"10.13039\/100011072","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Colorado Antiviral Pharmacology Laboratory at the University of Colorado","award":["R01AI145453"],"award-info":[{"award-number":["R01AI145453"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Objectives<\/jats:title>\n                  <jats:p>The active metabolites of HIV pre-exposure prophylaxis (PrEP)\u2014tenofovir-diphosphate and emtricitabine-triphosphate\u2014can be measured in dried blood spots (DBSs) to monitor patient adherence. To this end, multiple HPLC-MS\/MS assays have been developed. To inform DBS clinical application by characterizing (i) bias between two HPLC-MS\/MS approaches (direct versus indirect measurement) to quantify tenofovir-diphosphate\/emtricitabine-triphosphate in DBS; and (ii) room temperature (RT) storage stability.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Thirty-eight DBS cards from adults taking emtricitabine\/tenofovir disoproxil fumarate or emtricitabine\/tenofovir alafenamide for PrEP were analysed by UNC Clinical Pharmacology and Analytical Chemistry Core (CPAC) and Colorado Antiviral Pharmacology Laboratory (CAVP) using published methods. Samples were selected from larger clinical trial datasets to represent a wide range of clinically relevant concentrations. CPAC extracts one 3\u2005mm DBS punch using a directly measured metabolite method, whereas CAVP extracts either one 3\u2005mm (emtricitabine\/tenofovir disoproxil fumarate) or two 7\u2005mm (emtricitabine\/tenofovir alafenamide) DBS punches using an indirect method. Concentrations were converted to fmol\/mm\u00b2. Bias was assessed by CPAC:CAVP concentration ratios and linear regression. Percent change versus time at RT was fit to a nonlinear regression model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>CPAC tenofovir-diphosphate was higher [median (IQR) ratio\u200a=\u200a1.60 (1.38\u20131.75)] correlating strongly with CAVP (r2\u200a=\u200a0.97). CPAC emtricitabine-triphosphate was similar [median (IQR)\u200a=\u200a1.08 (1.05\u20131.20)] and correlated (r2\u200a=\u200a0.90) only for CAVP\u2019s 3\u2005mm assay. Tenofovir-diphosphate\/emtricitabine-triphosphate RT decay fit a three-parameter exponential decay model (r2\u200a=\u200a0.87).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A 1.6-fold bias adjustment is needed for tenofovir-diphosphate concentrations between assays. When punch size is matched, emtricitabine-triphosphate adjustment is unnecessary, otherwise variability confounds comparison. Bias and stability adjustments aid clinical interpretation for real-world application of this adherence monitoring technique.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf279","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T19:58:00Z","timestamp":1755028680000},"page":"2727-2731","source":"Crossref","is-referenced-by-count":0,"title":["Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6948-5202","authenticated-orcid":false,"given":"Nathan","family":"Engel","sequence":"first","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , 301 Pharmacy Ln, Chapel Hill, NC 27599 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Sykes","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , 301 Pharmacy Ln, Chapel Hill, NC 27599 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda P","family":"Schauer","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , 301 Pharmacy Ln, Chapel Hill, NC 27599 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela D M","family":"Kashuba","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , 301 Pharmacy Ln, Chapel Hill, NC 27599 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter L","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , 12850 East Montview Blvd, Aurora, CO 80045 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lane R","family":"Bushman","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , 12850 East Montview Blvd, Aurora, CO 80045 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mackenzie L","family":"Cottrell","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , 301 Pharmacy Ln, Chapel Hill, NC 27599 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"2025100314231765200_dkaf279-B1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jpba.2017.10.030","article-title":"Validation of an LC-MS\/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots","volume":"149","author":"Schauer","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"2025100314231765200_dkaf279-B2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo","year":"2015","journal-title":"N Engl J Med"},{"key":"2025100314231765200_dkaf279-B3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme","year":"2012","journal-title":"N Engl J Med"},{"key":"2025100314231765200_dkaf279-B4","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"2025100314231765200_dkaf279-B5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jpba.2016.01.038","article-title":"Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots","volume":"122","author":"Zheng","year":"2016","journal-title":"J Pharm Biomed Anal"},{"key":"2025100314231765200_dkaf279-B6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1089\/aid.2020.0108","article-title":"Individualized adherence benchmarks for HIV pre-exposure prophylaxis","volume":"37","author":"Ibrahim","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025100314231765200_dkaf279-B7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/QAI.0000000000002354","article-title":"Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following tenofovir alafenamide: the TAF-DBS study","volume":"84","author":"Yager","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025100314231765200_dkaf279-B8","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/cpt.2845","article-title":"A novel algorithm to improve prep adherence monitoring using dried blood spots","volume":"113","author":"Devanathan","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"2025100314231765200_dkaf279-B9","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1093\/cid\/ciae212","article-title":"Tenofovir-diphosphate and emtricitabine-triphosphate adherence benchmarks in dried blood spots for persons with HIV receiving tenofovir alafenamide and emtricitabine-based antiretroviral therapy (QUANTI-TAF)","volume":"79","author":"Coyle","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025100314231765200_dkaf279-B10","doi-asserted-by":"publisher","first-page":"e01710-17","DOI":"10.1128\/AAC.01710-17","article-title":"Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy","volume":"62","author":"Anderson","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025100314231765200_dkaf279-B11","doi-asserted-by":"publisher","first-page":"739","DOI":"10.4155\/bio-2023-0057","article-title":"Application of novel plasma separation filter cards for quantification of nucleoside\/nucleotide reverse transcriptase inhibitor di\/triphosphates in dried blood spots using LC-MS","volume":"15","author":"Thompson","year":"2023","journal-title":"Bioanalysis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/10\/2727\/63978212\/dkaf279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/10\/2727\/63978212\/dkaf279.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:23:23Z","timestamp":1759515803000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/10\/2727\/8225542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":11,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,8,7]]},"published-print":{"date-parts":[[2025,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf279","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,8,7]]}}}